Copyright
©The Author(s) 2025.
World J Cardiol. Mar 26, 2025; 17(3): 104000
Published online Mar 26, 2025. doi: 10.4330/wjc.v17.i3.104000
Published online Mar 26, 2025. doi: 10.4330/wjc.v17.i3.104000
Table 1 Baseline characteristics of patients across trials included in the analysis, n (%)
| Intervention | Mangner et al[16], 2019 | Brinkert et al[10], 2019 | Brinkert et al[9], 2021 | van Ginkel et al[11], 2025 | ||||
| Interruption of OAC (n = 299) | Continuation of OAC (n = 299) | Interruption of OAC (n = 185) | Continuation of OAC (n = 186) | Interruption of OAC (n = 733) | Continuation of OAC (n = 584) | Interruption of OAC (n = 427) | Continuation of OAC (n = 431) | |
| Interruption period | NA | 48-96 hours prior to TAVR | 48-96 hours prior to TAVR | DOACs: 48 hours prior to TAVR, except for those with glomerular filtration rate 50-80 mL/minute per 1.73 m3 and 30-50 mL/minute per 1.73 m3 on Dabigatran, who stopped 72 hours and 96 hours prior, respectively | ||||
| Acenocoumarol 72 hours prior | ||||||||
| Phenprocoumon or warfarin 120 hours prior | ||||||||
| Age (years), mean (SD) | 80 (76-83) | 80 (77-84) | NA | NA | 82 (78–86) | 82 (78–85) | 80.9 (SD = 6.2) | 81.4 ± 5.6 |
| Male | 127 (42.5) | 135 (45.2) | NA | NA | 351 (48) | 297 (51) | 289 (68) | 273 (63) |
| Median body-mass index | 27.9 (25.0-32.0) | 27.7 (24.5-31.5) | NA | NA | 27.1 (24.0–30.8) | 27.1 (24.0–30.8) | 26.9 (IQR = 24.3–30.8) | 26.5 (IQR = 24.2–29.7) |
| Atrial fibrillation | 299 (100) | 299 (100) | 95% of total sample size | 95% of total sample size | 644 (94) | 500 (97) | 406 (95.1) | 414 (96.1) |
| CHA2DS2-VASc score | 6 (5-6) | 5 (5-6) | 5.1 (SD = 1.5) | 5.1 (SD = 1.5) | 5 (4–6) | 5 (4–6) | 4.4 (SD = 1.4) | 4.5 ± 1.4 |
| Hypertension | 289 (96.7) | 291 (97.3) | NA | NA | 664 (91) | 525 (90) | 322 (75.4) | 339 (78.7) |
| Previous coronary artery disease | 131 (43.8) | 126 (42.3) | NA | NA | NA | NA | 206 (48.2) | |
| Diabetes mellitus | 162 (54.2) | 126 (42.3) | NA | NA | 277 (38) | 204 (35) | 206 (48.2) | 207 (48.0) |
| Previous cerebrovascular incident | 39 (13.0) | 48 (16.1) | 45 (24) | 26 (14) | 118 (16) | 90 (15) | 101 (24) | 88 (20) |
| Peripheral arterial vascular disease | NA | NA | NA | NA | 88 (12) | 75 (13) | 85 (19.9) | 79 (18.3) |
| Chronic obstructive pulmonary disease | 47 (15.7) | 47 (15.7) | NA | NA | NA | NA | 221 (51.8) | 213 (49.4) |
| Chronic renal insufficiency | 101 (33.9) | 95 (32.0) | NA | NA | NA | NA | 49 (11.5) | 68 (15.8) |
| Previous pacemaker implantation | NA | NA | NA | NA | 101 (14) | 114 (20) | 88 (20.6) | 75 (17.4) |
| Type of anticoagulation | VKA: 299 (100) | VKA: 117 (39). DOACs: 182 (61) | VKA: 100 (54). DOACs: 85 (46) | VKA: 131 (70). DOACs: 55 (30) | VKA: 511 (70). DOACs: 222 (30) | VKA: 294 (50). DOACs: 290 (50) | Multicentric study, with variations among different trial sites | Multicentric study, with variations among different trial sites |
- Citation: Goyal A, Shoaib A, Fareed A, Jawed S, Khan MT, Salim N, Zameer U, Siddiqui A, Thakur T, Sulaiman SA. Outcomes of periprocedural continuation vs interruption of oral anticoagulation in transcatheter aortic valve replacement. World J Cardiol 2025; 17(3): 104000
- URL: https://www.wjgnet.com/1949-8462/full/v17/i3/104000.htm
- DOI: https://dx.doi.org/10.4330/wjc.v17.i3.104000